SCHAUMBURG, Ill. , Nov. 26, 2025 /PRNewswire/ -- Cure SMA , the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of Itvisma™ (onasemnogene abeparvovec-brve) by Novartis for adults and children 2 years of age and older living with SMA and all types of SMA.

This newly approved one-time gene therapy delivers a functional SMN1 gene to motor neurons, helping restore SMN protein production and potentially slowing or halting SMA progression. Clinical data showed that Itvisma can improve motor function, provide rapid therapeutic benefit, and expand treatment options for older children and adults.

"This approval represents a long-awaited milestone for our SMA community," said Kenneth Hobby, President a

See Full Page